Laprophan Acquires Majority Stake in Swiss Pharmaceutical Firm Rivopharm
Posted on Jul 3, 2026
Laprophan Group, a leading Moroccan pharmaceutical group, has completed the acquisition of a majority stake in the Swiss pharmaceutical company Rivopharm. The cross-border transaction marks a significant expansion for the buyer within the international generic drug market.
With an annual revenue of approximately USD 100 million and a workforce of over 200 employees, Rivopharm specializes in the production of generic drugs dedicated to antibiotic, antidepressant, and anti-inflammatory therapies, as well as treatments for epilepsy and angina. The acquisition significantly broadens the Moroccan group's global footprint, as the Swiss manufacturer currently distributes its pharmaceutical products across more than 50 countries worldwide.
A multijurisdictional team of legal advisors facilitated the transaction. A&O Shearman advised Laprophan on the deal, with a legal team led by partners Paolo Nastasi and Francesca Croci, supported by associates Matteo Bortolamai and Houda Latrech. Rivopharm was assisted by White & Case, with a team composed of partners Leonardo Graffi and Giovanni Spedicato, alongside associates Daniele Pojani and Chiara Pacini.
